MASS-C Study: CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (Commercial Labs)

This fixed-price contract action was awarded on a full-and-open, competitive basis to Quest Diagnostics Inc. as a result of its propoals submitted in response to solicitation 75D301-22-R-72117. Performance Start Date: 3/07/2022 Performance Period: Base 11-month period, and one (1) 12-month option period Awarded Jurisdictions: AK, AL, AR, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, ME, MI, MN, MO, MS, MT, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SD, TN, TX, UT, VT, WA, WI, WV, and WY Total Contract Value: $19, 522,192.00 Total Funded Amount: $7,774,000.00 Place of Contract Performance: Contractor Location The primary purpose of the multistate assessment of SARS-CoV-2 Seroprevalence in Commercial Laboratory Survey (MASS-C) is to estimate the proportion of people that have been infected by or vaccinated for SARS-CoV-2 during the ongoing epidemic over time, nationally, and by geographic location and demographic/pediatric subcategory. For the eleven (11) jurisdictions awarded by the contract, the Contractor will identify excess, remnant, or residual blood specimens from remaining volumes of previously obtained blood specimens for non-COVID-19 diagnostic or antibody testing. More specifically, the Contractor will collect and test mass amounts of specimens for CLIA-approved and/or EUA-approved ELISA, COVID-19 IgG and/or IgM serological assays, as well as reflexive microneutralization testing for specimens that are seropositive by qualitative anti-nucleocapsid assay. The Contractor will then provide CDC with data reports of aggregate findings after every 8-week collection/testing period, in addition to a final report at the end of the award performance period.